Corporate Action

Isofol’s rights issue fully subscribed – exercises overallotment for Japanese partner

By

GOTHENBURG, Sweden, 4 July 2025 – Isofol Medical AB (“Isofol” or the “Company”) today announces the outcome of the Company’s rights issue of units with preferential rights for the Company’s existing shareholders, as resolved by the Board of Directors on 12 May 2025 and approved by the Extraordinary General Meeting on 11 June 2025 (the […]

Isofol’s rights issue fully subscribed – exercises overallotment for Japanese partner Read More »

Isofol publishes prospectus in connection with the company’s rights issue

By

GOTHENBURG, Sweden, 17 June 2025 – The Board of Directors of Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (”Isofol” or the “Company”) announced on 12 May 2025 that it had resolved to carry out a rights issue of units, comprising shares and warrants, with preferential rights for the Company’s existing shareholders (the “Rights Issue”), amounting

Isofol publishes prospectus in connection with the company’s rights issue Read More »

Isofol announces final terms of the rights issue and the potential overallotment issue

By

GOTHENBURG, Sweden, 5 June 2025 – The Board of Directors of Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol” or the “Company”) announced on 12 May 2025, that the Board of Directors, subject to subsequent approval by an Extraordinary General Meeting of the Company on 11 June 2025, had resolved to carry out an issue

Isofol announces final terms of the rights issue and the potential overallotment issue Read More »

The Board of Directors of Isofol resolves on a fully guaranteed Rights Issue of units amounting to approximately SEK 85 million and proposes an over-allotment issue of approximately SEK 10 million

By

GOTHENBURG, Sweden, 12 May 2025 – The Board of Directors of Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol” or the “Company”) has today resolved on a new issue of units with preferential rights for the Company’s existing shareholders amounting to approximately SEK 85 million before issue costs and excluding the potential capital contribution that

The Board of Directors of Isofol resolves on a fully guaranteed Rights Issue of units amounting to approximately SEK 85 million and proposes an over-allotment issue of approximately SEK 10 million Read More »

Isofol’s Japanese partner Solasia intensifies its commitment to the clinical development of arfolitixorin

By

GOTHENBURG, Sweden, March 19, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol”), today announces that the company’s collaboration partner, the Japanese pharmaceutical company Solasia Pharma K.K. (“Solasia”), has confirmed its continued strong commitment in the development of arfolitixorin. Solasia will contribute with its expertise and participate in defining the detailed design of the

Isofol’s Japanese partner Solasia intensifies its commitment to the clinical development of arfolitixorin Read More »

Isofol presents a clinical development plan for arfolitixorin

By

GOTHENBURG, Sweden, March 19, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol”), today presents the company’s continued strategy and clinical development program for the drug candidate arfolitixorin. The board and management, together with external experts, have evaluated the available data for arfolitixorin and decided to conduct a clinical phase I/II study to document

Isofol presents a clinical development plan for arfolitixorin Read More »

Isofol’s board of directors announces its position on minority shareholder’s proposal ahead of extraordinary general meeting

By

GOTHENBURG, Sweden, December 13, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today that all of the company’s board members will leave their respective positions if Jan-Eric Österlund is elected as a new member of the board at the extraordinary general meeting that has been convened on a request from a group of

Isofol’s board of directors announces its position on minority shareholder’s proposal ahead of extraordinary general meeting Read More »

Isofol Medical AB (publ) publishes prospectus and new financial information in connection with listing on Nasdaq Stockholm

By

GOTHENBURG, Sweden, October 18, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), (“Isofol” or the “Company”), announced today that the prospectus prepared by the Company in connection with the listing on Nasdaq Stockholm has been approved and registered by the Swedish Financial Supervisory Authority (Finansinspektionen). The prospectus contains updated financial

Isofol Medical AB (publ) publishes prospectus and new financial information in connection with listing on Nasdaq Stockholm Read More »

Isofol raises SEK 500 million in oversubscribed rights issue and exercised over-allotment option

By

GOTHENBURG, Sweden, June 14, 2021 – Isofol Medical AB (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the “Company”) fully guaranteed new share issue with preferential rights for the Company’s existing shareholders (the “Rights Issue”), which ended on June 10, 2021, was oversubscribed. Due to the strong demand from strategic investors, a directed

Isofol raises SEK 500 million in oversubscribed rights issue and exercised over-allotment option Read More »

Isofol publishes prospectus in connection with the fully guaranteed preferential rights issue of approximately SEK 400 million

By

GOTHENBURG, Sweden, May 25, 2021 – Isofol Medical AB’s (publ), (Nasdaq First North Premier Growth Market: ISOFOL), (“Isofol or the “Company”) Board of Directors resolved on May 18, 2021, on an issue of shares of a maximum of 62,524,474 shares with preferential rights for the Company’s existing shareholders (the “Rights Issue”). If the Rights Issue

Isofol publishes prospectus in connection with the fully guaranteed preferential rights issue of approximately SEK 400 million Read More »

Scroll to Top